In another study involving 536 patients with KRAS-mutant lung adenocarcinoma, both STK11 and KEAP1 mutations in the presence of a KRAS mutation were associated with poor response rates to anti-PD-L1 inhibitors. This evidence concerns the gene KRAS and lung adenocarcinoma.